Goldman Sachs
MYGN icon

Goldman Sachs’s Myriad Genetics MYGN Stock Holding History

Goldman Sachs’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,400
Closed -$41K – 5871
2018
Q1 		$41K Sell
1,400
-2,100
-60% -$71.1K ﹤0.01% 5529
2017
Q4 		$120K Sell
3,500
-8,400
-71% -$283K ﹤0.01% 5679
2017
Q3 		$431K Sell
11,900
-47,700
-80% -$1.36M ﹤0.01% 5199
2017
Q2 		$1.54M Buy
59,600
+24,700
+71% +$524K ﹤0.01% 4057
2017
Q1 		$670K Buy
34,900
+9,500
+37% +$168K ﹤0.01% 4745
2016
Q4 		$423K Sell
25,400
-172,800
-87% -$3.13M ﹤0.01% 5194
2016
Q3 		$4.08M Sell
198,200
-372,900
-65% -$9.46M ﹤0.01% 3212
2016
Q2 		$17.5M Buy
571,100
+531,200
+1,331% +$18.5M 0.01% 1889
2016
Q1 		$1.49M Sell
39,900
-600
-1% -$22.6K ﹤0.01% 3740
2015
Q4 		$1.75M Sell
40,500
-145,200
-78% -$6.13M ﹤0.01% 3762
2015
Q3 		$6.96M Buy
185,700
+141,500
+320% +$5.02M ﹤0.01% 2576
2015
Q2 		$1.5M Buy
44,200
+36,100
+446% +$1.23M ﹤0.01% 4139
2015
Q1 		$287K Sell
8,100
-54,200
-87% -$1.94M ﹤0.01% 5685
2014
Q4 		$2.12M Buy
62,300
+30,000
+93% +$1.06M ﹤0.01% 3780
2014
Q3 		$1.25M Sell
32,300
-45,700
-59% -$1.71M ﹤0.01% 4391
2014
Q2 		$3.04M Sell
78,000
-272,700
-78% -$10.1M ﹤0.01% 3571
2014
Q1 		$12M Sell
350,700
-1,842,700
-84% -$57.1M ﹤0.01% 2207
2013
Q4 		$46M Buy
2,193,400
+2,029,400
+1,237% +$51.3M 0.02% 1105
2013
Q3 		$3.85M Buy
164,000
+11,300
+7% +$321K ﹤0.01% 3218
2013
Q2 		$4.1M Buy
+152,700
New +$4.43M ﹤0.01% 2948

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's MYGN Position: Q1 2026 in Review

Goldman Sachs increased its Myriad Genetics (MYGN) stake by 9.5% in Q1 2026, buying an estimated $1.07M and bringing the position to 2,366,092 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

Goldman Sachs first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.8M in Q3 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Goldman Sachs held 2,366,092 shares of Myriad Genetics worth $10.6M as of Q1 2026.
  • Goldman Sachs bought 205,810 Myriad Genetics shares in Q1 2026, an estimated $1.07M.
  • Myriad Genetics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3020 holding.
  • Goldman Sachs first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Myriad Genetics position peaked at $68.8M in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.